Laden…
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Fentanyl is a highly potent synthetic opioid that is primarily used as an analgesic and anesthetic. It acts as an agonist at the μ-opioid receptor and has a high potential for addiction and dependence. Due to its strong effects, there is a significant risk of respiratory depression and overdose. Fentanyl is used under medical supervision but is also associated with a high risk of abuse and death.
Class
Opioide
Pharmacological context
Mechanism
Fentanyl acts as an agonist at μ-opioid receptors in the central...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
High Risk
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: N-(1-phenethyl-4-piperidyl)-N-phenyl-propionamide
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Synapedia Evidence
Fentanyl acts as an agonist at μ-opioid receptors in the central nervous system, leading to significant pain relief. It also affects the reward system, contributing to a high potential for dependence.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 200–400 µg
Total duration 1–3 hours (intravenous), 72 hours (transdermal)
Sublingual
| Tier | Dosage |
|---|---|
| Light | 100–200 µg |
| Reported | 200–400 µg |
| Strong | 400–800 µg |
IV
| Tier | Dosage |
|---|---|
| Light | 0.5–1 µg/kg |
| Reported | 1–2 µg/kg |
| Strong | 2–5 µg/kg |
Transdermal
| Tier | Dosage |
|---|---|
| Light | 12 µg/h |
| Reported | 25–50 µg/h |
| Strong | 75–100 µg/h |
Onset
1–5 minutes (intravenous), 12–24 hours (transdermal)
Peak
30–60 minutes (intravenous), 24–36 hours (transdermal)
Total duration
1–3 hours (intravenous), 72 hours (transdermal)
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Evidence
strong
Safer Use
Depressant-risk context
This substance belongs to a context where combinations with opioids, benzodiazepines, alcohol, GHB/GBL, or other sedating substances can increase sedation, blackout, aspiration, and breathing-risk patterns. Risk Check can review warning patterns; it is not medical advice and it cannot clear a combination as safe.
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.